Zhong Xiaojing, Ying Jiyuan, Liao Haihong, Shen Liying, Pan Yunfei
Department of Endocrinology, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, 313000, China.
Department of Gastroenterology, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 313000, China.
Future Oncol. 2022 Jun;18(18):2289-2300. doi: 10.2217/fon-2021-1537. Epub 2022 Apr 20.
Thyroid function abnormality (TFA) is one of the most common toxicities in non-small-cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors. However, the risk factors related to TFA and the relationship between TFA and prognosis in NSCLC are not fully clarified. We conducted a retrospective study of patients with advanced NSCLC who were treated with PD-1 inhibitors in Huzhou Central Hospital. Thyroid function test was carried out using electrochemiluminescent bridging immunoassay. The association between TFA and clinical outcome was investigated. A total of 273 patients were included in this study. Patients who experienced TFA had longer progression-free survival (21.9 vs 6.4 months; p < 0.001) and overall survival (44.6 vs 24.1 months; p = 0.02) than patients without TFA. After multivariate analysis, TFA was an independent prognostic factor for progression-free and overall survival (p < 0.05). TFA is associated with better outcome in NSCLC patients who receive immunotherapy.
甲状腺功能异常（TFA）是接受免疫检查点抑制剂治疗的非小细胞肺癌（NSCLC）患者中最常见的毒性反应之一。然而，与TFA相关的危险因素以及NSCLC中TFA与预后的关系尚未完全阐明。我们对在湖州市中心医院接受PD-1抑制剂治疗的晚期NSCLC患者进行了一项回顾性研究。采用电化学发光桥联免疫分析法进行甲状腺功能检测。研究了TFA与临床结局之间的关联。本研究共纳入273例患者。发生TFA的患者与未发生TFA的患者相比，无进展生存期更长（21.9个月对6.4个月；p<0.001），总生存期也更长（44.6个月对24.1个月；p=0.02）。多因素分析后，TFA是无进展生存期和总生存期的独立预后因素（p<0.05）。在接受免疫治疗的NSCLC患者中，TFA与更好的结局相关。
